Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ALLO Allogene Therapeutics

10.620
-0.220-2.03%
Close 09/23 16:00 ET
10.700
+0.080+0.75%
Post Mkt Price 09/23 17:28 ET
High
10.790
Open
10.540
Turnover
45.59M
Low
10.250
Pre Close
10.840
Volume
4.35M
Market Cap
1.53B
P/E(TTM)
Loss
52wk High
26.210
Shares
143.81M
P/E(Static)
Loss
52wk Low
6.425
Float Cap
869.24M
Bid/Ask %
0.00%
Historical High
55.000
Shs Float
81.85M
Volume Ratio
1.77
Historical Low
6.425
Dividend TTM
--
Div Yield TTM
45
P/B
1.90
Dividend LFY
--
Div Yield LFY
423.73%
Turnover Ratio
5.32%
Amplitude
4.98%
Avg Price
10.470
Lot Size
1
Float Cap
869.24M
Bid/Ask %
0.00%
Historical High
55.000
Shs Float
81.85M
Volume Ratio
1.77
Historical Low
6.425
Dividend TTM
--
P/B
1.90
Dividend LFY
--
Turnover Ratio
5.32%
Amplitude
4.98%
Avg Price
10.470
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
CEO: Dr. David D. Chang, M.D.,PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...